Literature DB >> 15681256

DRESS syndrome in a patient on sulfasalazine for rheumatoid arthritis.

Fabrice Michel1, Jean-Christophe Navellou, Denis Ferraud, Eric Toussirot, Daniel Wendling.   

Abstract

DRESS (Drug Rash with Eosinophilia and Systemic Symptoms) is a drug-induced hypersensitivity syndrome that can mimic malignant lymphoma. We report a case in a 63-year-old woman who had been on sulfasalazine for 2 months to treat rheumatoid arthritis. She was admitted a few days after onset of a flu-like syndrome with a pruriginous maculopapular erythema initially involving the face, trunk, and proximal limbs; a fever of 41 degrees C; and enlargement of the liver, spleen, and several peripheral lymph nodes. Blood tests showed marked eosinophilia (9300/mm3), lymphocytosis, hyperbasophilic cells, and severe inflammation. DRESS syndrome was diagnosed. An indirect immunofluorescence assay for human herpesvirus 6 (HHV6) was positive, supporting recent HHV6 infection. Primary HHV6 infection and HHV6 reactivation have been incriminated in the genesis of DRESS syndrome. DRESS syndrome continues to carry a high mortality rate of about 10%. Drugs previously reported to cause DRESS syndrome include sulfasalazine, hydantoin, d-penicillamine, allopurinol, hydrochlorothiazide, and cyclosporine. A high index of suspicion for DRESS syndrome should be maintained in patients receiving these drugs. Serological tests for HHV6 should be performed routinely in patients with suspected DRESS syndrome, although uncertainty persists about the link between HHV6 infection and DRESS syndrome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15681256     DOI: 10.1016/j.jbspin.2004.06.002

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  14 in total

1.  Drug reaction with eosinophilia and systemic symptoms.

Authors:  Elisabeth De Greef; Katie Mennie; Aleixo Muise
Journal:  CMAJ       Date:  2009-11-23       Impact factor: 8.262

Review 2.  Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy.

Authors:  Rebecca Pavlos; Simon Mallal; David Ostrov; Yuri Pompeu; Elizabeth Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2014 Jan-Feb

3.  DRESS syndrome associated with influenza virus.

Authors:  Raghavendra L Girijala; Aishwarya Ramamurthi; David Wright; Young Kwak; Leonard H Goldberg
Journal:  Proc (Bayl Univ Med Cent)       Date:  2019-03-28

4.  Persistent eosinophilia in rheumatoid arthritis: a prospective observational study.

Authors:  Dantis Emmanuel; Subhash Chandra Parija; Ankit Jain; Durga Prasanna Misra; Rakhee Kar; Vir Singh Negi
Journal:  Rheumatol Int       Date:  2018-11-13       Impact factor: 2.631

5.  Drug-induced hypersensitivity syndrome associated with reactivation of human herpesvirus 6 presenting with severe hepatic injury.

Authors:  Hideaki Miura; Masayuki Nakano; Naoki Yoshimura; Shigehiro Kitamura; Haruki Yamada; Masakazu Takazoe
Journal:  Clin J Gastroenterol       Date:  2008-09-03

Review 6.  DRESS syndrome: a case report and literature review.

Authors:  Cláudia Sofia Cardoso; Ana Margarida Vieira; Ana Paula Oliveira
Journal:  BMJ Case Rep       Date:  2011-06-03

7.  An unusual case of DRESS syndrome due to leflunomide.

Authors:  Arvind Kumar Vaish; Anil Kumar Tripathi; Lokesh Kumar Gupta; Nirdesh Jain; Abhishek Agarwal; Sudhir Kumar Verma
Journal:  BMJ Case Rep       Date:  2011-09-04

Review 8.  [Dermatological symptoms in rheumatology].

Authors:  E Aberer
Journal:  Z Rheumatol       Date:  2008-09       Impact factor: 1.372

Review 9.  Hepatic manifestations of non-steroidal inflammatory bowel disease therapy.

Authors:  Robert Hirten; Keith Sultan; Ashby Thomas; David E Bernstein
Journal:  World J Hepatol       Date:  2015-11-28

Review 10.  Severe Delayed Drug Reactions: Role of Genetics and Viral Infections.

Authors:  Rebecca Pavlos; Katie D White; Celestine Wanjalla; Simon A Mallal; Elizabeth J Phillips
Journal:  Immunol Allergy Clin North Am       Date:  2017-11       Impact factor: 3.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.